Adicet Bio Inc stock is traded at $2.94, with a volume of 38,151. It is up +0.68% in the last 24 hours and down -52.96% over the past month. Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Previous Close:
$2.92
Open:
$2.89
24h Volume:
38,151
Relative Volume:
0.17
Market Cap:
$27.52M
Revenue:
$24.99M
Net Income/Loss:
-$108.83M
P/E Ratio:
-
EPS:
-$15.03
Net Cash Flow:
-$91.62M
1W Performance:
-14.04%
1M Performance:
-52.96%
6M Performance:
-65.61%
1Y Performance:
-72.85%
1-Day Range:
$2.89$3.03
1-Week Range:
$2.87$3.47
52-Week Range:
$2.87$11.37
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio IncSector
HealthcareIndustry
BiotechnologyPhone
617-482-2333Address
131 DARTMOUTH STREET, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS